We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Testing Device Integrates Robotic Phlebotomy with Sample Processing

By LabMedica International staff writers
Posted on 20 Jun 2018
Print article
Image: Desktop systems have been created that can automatically take patient blood samples (robotic phlebotomy) and process them without any human intervention. Making such technology available for hospitals and clinics may have significant consequences, as blood draws are the most common clinical procedures (Photo courtesy of Rutgers University).
Image: Desktop systems have been created that can automatically take patient blood samples (robotic phlebotomy) and process them without any human intervention. Making such technology available for hospitals and clinics may have significant consequences, as blood draws are the most common clinical procedures (Photo courtesy of Rutgers University).
Diagnostic blood testing is the most commonly performed clinical procedure in the world and influences the majority of medical decisions made in hospital and laboratory settings. However, manual blood draw success rates are dependent on clinician skill and patient physiology.

Results from such tests are generated almost exclusively in centralized laboratories from large-volume samples using labor-intensive analytical techniques. An end-to-end blood-testing device has been developed that integrates robotic phlebotomy with downstream sample processing. This platform device performs blood draws and provides diagnostic results in a fully automated fashion at the point-of-care.

Biomedical engineers at Rutgers University, Piscataway NJ, USA) created a device that includes an image-guided venipuncture robot, to address the challenges of routine venous access, with a centrifuge-based blood analyzer to obtain quantitative measurements of hematology. The team first demonstrated a white blood cell assay on the analyzer, using a blood mimicking fluid spiked with fluorescent microbeads, where the area of the packed bead layer is correlated with the bead concentration. Next the scientists performed studies to evaluate the pumping efficiency of the sample-handling module. Finally, studies were conducted on the integrated device from blood draw to analysis, using blood vessel phantoms to assess the accuracy and repeatability of the resulting white blood cell assay.

Martin Yarmush, MD, PhD, a Distinguished Professor of Biomedical Engineering and the senior author of the study said, “This device represents the holy grail in blood testing technology. Integrating miniaturized robotic and microfluidic systems, this technology combines the breadth and accuracy of traditional laboratory testing with the speed and convenience of point-of-care testing.” The study was published on May 30, 2018, in the journal Technology.

Related Links:
Rutgers University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.